Novartis Ag (NVS) Change in Cash (2009 - 2025)
Novartis Ag recorded quarterly Change in Cash of -$410.0 million in Q2 2025, up 92.53% quarter-over-quarter from -$5.5 billion in Q4 2024, and up 73.82% year-over-year from -$235.9 million in Q2 2024.
Novartis Ag's Change in Cash history runs 17 years deep, the most recent figure standing at -$410.0 million for Q2 2025.
- In Q2 2025, Change in Cash rose 73.82% year-over-year to -$410.0 million; the TTM figure through Jun 2025 stood at -$1.8 billion (up 83.2% YoY), while the FY2025 annual figure was -$24.0 million, up 98.76% from the prior year.
- Change in Cash came in at -$410.0 million for Q2 2025 at Novartis Ag, up from -$5.5 billion in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $5.7 billion in Q3 2024 to a low of -$10.2 billion in Q2 2022.
- A 5-year average of -$2.4 billion and a median of -$1.3 billion in 2023 frame the typical range for Change in Cash.
- Across the five-year window, Change in Cash tumbled 877.13% in 2022 and surged 111.25% in 2023, its largest moves.
- Novartis Ag's Change in Cash stood at -$4.5 billion in 2021, then sank by 93.39% to -$8.8 billion in 2022, then soared by 111.25% to $988.0 million in 2023, then plunged by 655.67% to -$5.5 billion in 2024, then surged by 92.53% to -$410.0 million in 2025.
- According to Business Quant data, Change in Cash over the past three periods registered -$410.0 million, -$5.5 billion, and $5.7 billion for Q2 2025, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -410.00 Mn |
| Dec 31, 2024 | -5.49 Bn |
| Sep 30, 2024 | 5.71 Bn |
| Jun 30, 2024 | -1.57 Bn |
| Dec 31, 2023 | 988.00 Mn |
| Jun 30, 2023 | -1.12 Bn |
| Dec 31, 2022 | -8.78 Bn |
| Jun 30, 2022 | -10.23 Bn |
| Dec 31, 2021 | -4.54 Bn |
| Jun 30, 2021 | 1.32 Bn |
| Dec 31, 2020 | 664.00 Mn |
| Jun 30, 2020 | 1.39 Bn |
| Jun 30, 2019 | 3.18 Bn |
| Dec 31, 2018 | -729.00 Mn |
| Jun 30, 2018 | 6.74 Bn |
| Dec 31, 2017 | 50.00 Mn |
| Sep 30, 2017 | 954.00 Mn |
| Jun 30, 2017 | 284.00 Mn |
| Mar 31, 2017 | 565.00 Mn |
| Dec 31, 2016 | -167.00 Mn |
| Jun 30, 2016 | 579.00 Mn |
| Mar 31, 2016 | -217.00 Mn |
| Dec 31, 2015 | -654.00 Mn |
| Sep 30, 2015 | 110.00 Mn |
| Dec 31, 2014 | 110.00 |
| Jun 30, 2014 | -373.00 |
| Mar 31, 2014 | 483.00 |
| Dec 31, 2013 | 324.00 |
| Jun 30, 2013 | -629.00 |
| Mar 31, 2013 | -846.00 |
| Sep 30, 2012 | -7.00 |
| Jun 30, 2012 | 557.00 |
| Mar 31, 2012 | 332.00 |
| Dec 31, 2011 | -377.00 |
| Sep 30, 2011 | -145.00 |
| Dec 31, 2010 | -67.00 |
| Sep 30, 2010 | -172.00 |
| Jun 30, 2010 | 492.00 |
| Mar 31, 2010 | 2,172.00 |
| Dec 31, 2009 | 121.00 |
| Sep 30, 2009 | -817.00 |
| Jun 30, 2009 | 2,015.00 |
| Mar 31, 2009 | -463.00 |